Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. (FBRX) reported that director Barbara K. Finck disposed of multiple equity awards in connection with the closing of a merger under an Agreement and Plan of Merger. On August 27, 2026, several stock option grants and a block of restricted stock units were cancelled and converted, under the merger terms, into rights to receive cash based on a $77.00 per share Merger Consideration, while options with exercise prices at or above that amount were cancelled with no consideration.
Forte Biosciences, Inc. (FBRX) director Shivpreet Singh Kapoor reported the disposition of equity awards in connection with a merger under the July 26, 2026 Agreement and Plan of Merger among Forte, argenx BV and Avena Merger Sub Inc. Unexercised stock options with exercise prices below $77.00 per share and restricted stock units were canceled and converted into cash rights, while options with exercise prices at or above $77.00 were canceled for no consideration.
Forte Biosciences, Inc. (FBRX) reported that director Stephen K. Doberstein disposed of several equity awards in connection with a merger under an Agreement and Plan of Merger with argenx BV and Avena Merger Sub Inc. On 2026-08-27, multiple stock options and restricted stock units were cancelled and converted into cash rights pursuant to the merger terms.
Stock options with exercise prices below the $77.00 per share merger consideration, including grants for 2,000 shares at $29.50, 1,000 at $31.75, 1,000 at $20.00, 2,000 at $8.60, and 31,000 at $7.54, were cancelled and converted into a right to receive a lump-sum cash payment based on the excess of the merger consideration over the exercise price, multiplied by the shares subject to each option. Options with exercise prices at or above $77.00 per share were cancelled with no consideration.
In addition, 18,353 restricted stock units, each representing a contingent right to one share of common stock, were cancelled and converted into a lump-sum cash payment equal to the merger consideration multiplied by the number of underlying shares. The filing indicates these transactions were dispositions to the issuer rather than open-market trades, and the Rule 10b5-1 trading plan box was not checked.
Forte Biosciences, Inc. (FBRX) reported that its Chief Financial Officer, Antony A. Riley, disposed of all reported equity interests in connection with the completed acquisition of the company by argenx BV. On August 27, 2026, Riley tendered 42,600 shares of common stock in a transaction pursuant to a tender offer under a Merger Agreement, receiving $77.00 per share in cash, subject to withholding taxes. In-the-money Forte stock options and restricted stock units were canceled and converted into cash rights based on the same $77.00 Merger Consideration per underlying share, while options with exercise prices at or above that amount were canceled with no consideration.
Forte Biosciences, Inc. (FBRX) reports that CEO, Secretary and Chair Paul A. Wagner disposed of his equity interests in connection with the closing of a merger with argenx BV. On 2026-08-27, 85,482 shares of common stock were tendered and exchanged for $77.00 per share in cash under a tender offer, leaving no directly held common shares reported.
Pursuant to the merger agreement, multiple unexercised stock options with per-share exercise prices below $77.00 were canceled and converted into cash rights equal to the cash consideration minus the exercise price, multiplied by the number of option shares. Options with exercise prices at or above $77.00 were canceled with no payment. Outstanding restricted stock units were also canceled and converted into cash equal to $77.00 times the number of underlying shares.
Forte Biosciences, Inc. (FBRX) has been acquired by argenx BV through a cash tender offer followed by a merger. Avena Merger Sub Inc., a wholly owned subsidiary of argenx, commenced a tender offer at $77.00 per share in cash for all outstanding Forte common shares.
As of one minute after 11:59 p.m. Eastern Time on August 26, 2026, 19,894,879 shares had been validly tendered and not withdrawn, which, together with shares already owned by argenx, represented approximately 87.13% of Forte’s outstanding shares, satisfying all offer conditions. These shares were irrevocably accepted for payment, and on August 27, 2026, the merger was completed under Section 251(h) of the DGCL, making Forte a wholly owned subsidiary of argenx.
Each remaining share (other than specified excluded and appraisal shares) was converted into the right to receive the same $77.00 cash consideration, and holders of outstanding pre-funded warrants became entitled, upon exercise, to receive the merger consideration for the underlying shares. The acquirer used approximately $2.2 billion of cash on hand to fund the offer, equity awards, pre-funded warrants and related payments. Forte has requested that Nasdaq suspend trading and file Form 25 to delist the shares and plans to file Form 15 to terminate registration and suspend its Exchange Act reporting obligations. All pre-merger directors and officers resigned at the effective time and were replaced by the former directors and officers of Purchaser.
Forte Biosciences, Inc. (FBRX) is being acquired by Avena Merger Sub Inc., a wholly owned subsidiary of argenx, through a completed cash tender offer followed by a merger. The offer was for $77.00 per share in cash, without interest and subject to withholding taxes.
The offer expired at one minute after 11:59 p.m. Eastern Time on August 26, 2026, and was not extended. As of expiration, 19,894,879 shares had been validly tendered and not withdrawn, which, together with shares owned by argenx and its affiliates, represented approximately 87.13% of outstanding shares, satisfying the Minimum Condition. All tendered shares were accepted, and payment will be made promptly as provided in the offer and merger agreement.
After the offer, the buyer held enough shares to effect a merger under Section 251(h) of the DGCL without a Forte stockholder vote. Purchaser merged into Forte, which survives as a wholly owned subsidiary of argenx, and each remaining share (other than excluded and properly perfected appraisal shares) was converted into the right to receive $77.00 in cash. FBRX shares are expected to cease trading and be delisted from the Nasdaq Capital Market on August 27, 2026, and argenx plans to terminate the registration of the shares and suspend Forte’s reporting obligations under the Exchange Act.
Forte Biosciences, Inc. (FBRX) reports that the cash tender offer by Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV, has successfully closed at $77.00 per share. The offer expired at one minute after 11:59 p.m. Eastern Time on August 26, 2026 and was not extended.
Computershare advised that 19,894,879 shares were validly tendered and not withdrawn, which, together with shares already owned by argenx and its affiliates, represented about 87.13% of shares outstanding, satisfying the minimum tender condition. On August 27, 2026, argenx completed the merger under Section 251(h) of the DGCL, and all remaining eligible shares were converted into the right to receive $77.00 in cash per share. The common stock will be delisted from the Nasdaq Capital Market, and argenx plans to terminate FBRX’s registration and reporting obligations under the Exchange Act.
Forte Biosciences, Inc. (FBRX) is having its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934, as notified on Form 25. Nasdaq states it has complied with its rules under 17 CFR 240.12d2-2(b), and the issuer has complied with exchange rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal.
Forte Biosciences, Inc. (FBRX) filed an amendment to its Schedule 14D-9 regarding the cash tender offer by Avena Merger Sub Inc., a subsidiary of argenx BV, to acquire all Forte shares at an Offer Price of $77.00 per share. The amendment clarifies that, as of August 21, 2026, Forte’s executive officers have not reached understandings or signed agreements with argenx, the purchaser, or the surviving corporation about post-closing employment, restrictive covenants, or equity participation, though such discussions may occur before closing.
The amendment adds detail on the unaudited long‑term financial projections used by the Forte board and Guggenheim Securities, confirms these projections were not provided to argenx or the purchaser, and elaborates on Guggenheim’s discounted cash flow assumptions, including a discount rate range and a negative terminal growth rate after anticipated loss of exclusivity for FB102. It also discloses Guggenheim’s estimated $43 million transaction fee (partly offset by a $2.0 million opinion fee already paid) and summarizes precedent M&A premium analyses and analyst target price ranges relative to the $77.00 Offer Price. Forte reports receiving nine demand letters alleging disclosure deficiencies and states it believes these claims are without merit; as of August 21, 2026, it is not aware of lawsuits challenging the transaction or disclosures.